CHARACTERISTICS OF LDL-C ELEVATION AND THE TREATMENT OUTCOMES OF ROSUVASTATIN IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AT TRA VINH GENERAL HOSPITAL 2021-2022

Abstract

Background: Myocardial infarction (MI), sometimes referred to as a heart attack, is a leading cause of mortality on a global scale. This medical ailment is sometimes referred to as a myocardial infarction. To mitigate the issue, it is essential to promptly conduct diagnostic examinations and start therapy for lipid abnormalities. Objectives: The aim of this study is to provide a comprehensive description of the variables associated with elevated low-density lipoprotein cholesterol (LDL-c) levels and to evaluate the treatment results of rosuvastatin in patients diagnosed with acute myocardial infarction at Tra Vinh General Hospital throughout the period of 2021-2022. Materials and methods: The objective of each of these experiments was to ascertain the attributes associated with high lowdensity lipoprotein cholesterol (LDL-c). Both of these trials were designed to be carried out on individuals who had a previous record of increased levels of low-density lipoprotein cholesterol (LDL-c). Enumerated here are the many procedures and components: A total of 199 individuals were included in a cross-sectional research, all of whom presented with both early-onset acute myocardial infarction and dyslipidemia. The aforementioned people originated from four separate familial lineages characterized by a historical prevalence of the aforementioned ailment. The research described in this study was conducted inside the Department of Cardiology-Geriatrics, with no intervention being necessary. Results: The findings indicate that 52.5% of those who had LDL-c level assessments demonstrated ideal levels, while 24.2% exhibited levels that were somewhat near to the normal range. Additionally, 3.0% of the participants displayed LDL-c levels that significantly above the normal range. Following the conclusion of the therapeutic intervention, the LDL-c concentrations of the participants exhibited a notable reduction, with an average value of 1.10±0.61mmol/L. Furthermore, a significant proportion of the participants, namely 63.8%, achieved the predetermined control objective. Conclusions: The administration of the rosuvastatin regimen has been shown to be a highly successful approach in attaining the necessary elevation of LDL-c levels, hence playing a crucial role in the management and prevention of many medical conditions among patients and their families.